Myriad Genetics is the only place to go for BRCA1/BRCA2 mutation testing. The Salt Lake City biopharmaceutical company has a monopoly on the test. Its scientists discovered the BRCA1 and BRCA2 genes in 1996 and patented their use for assessing the risk of genetically related cancer.
Myriad Genetics is the only place to go for BRCA1/BRCA2 mutation testing. The Salt Lake City biopharmaceutical company has a monopoly on the test. Its scientists discovered the BRCA1 and BRCA2 genes in 1996 and patented their use for assessing the risk of genetically related cancer.
According to a Myriad spokesperson, 50,000 BRCA1 and BRCA2 genetic tests were performed in 2006, compared with 35,000 in 2005. The firm expects demand to rise again about 43% this year. The automated gene sequencing technology covers 85% to 90% of genetically related breast cancer. Results from about 15 of every 100 tests are positive.
Testing charges vary. It costs $3200 to test the first person in a family, according to Robert Resta, a genetic counselor with Swedish Medical Center in Seattle. Testing first-degree relatives-parents, siblings, and children-costs an additional $400 per person. For Ashkenazi Jews, the test costs about $500 because their susceptibility is based on fewer mutations than the general population, thereby requiring a simpler test, Resta said.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
Is the Kaiser Score More Effective than BI-RADS for Assessing Contrast-Enhanced Mammography and MRI?
October 14th 2024For women with breast-enhanced masses, Kaiser scoring (KS) demonstrated a 20 percent higher AUC than BI-RADS classification for contrast-enhanced mammography (CEM) and was comparable to KS for breast MRI.